Long only, growth, momentum, contrarian

BioLineRx Offers Investors Multiple Upcoming Catalysts At Currently Depressed Share Price

Failure of a company's lead product candidate in clinical trials is often catastrophic for existing shareholders of a development phase pharmaceutical company. I have first-hand experience with significant losses from multiple investments over the last decade in which I had foolishly held large holdings through such binary events believing that positive news or FDA approval was imminent. While existing shareholders may often be hard-pressed to recoup their losses for quite some time, I believe the oversold condition in these companies' common shares created by these lead-candidate failures can create potentially-lucrative entries for new shareholders with the foresight and knowledge to see past such disappointments.

BioLineRx (BLRX) experienced one such setback on March 20th of this year. The company...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details